Background
Coronary computed tomographic angiography (CCTA) has become an excellent rule-out test for suspect coronary artery disease (CAD). The recommendation for CCTA was even expanded by one national guideline as a first line test to patients with intermediate and high likelihood of CAD based on their cost-effectiveness analysis suggesting that this would be a lower cost strategy. However, the relative low specificity of CCTA in the diagnosis of functional myocardial ischemia makes it difficult to act as a real gatekeeper for the patients to be referred to invasive coronary angiography (ICA). In developing country like China, for the patients with prior CCTA test who are subject to downstream ICA, over 30% of them were found to be no obstructive CAD [1] . Even more, the invasive procedure seems to be much more frequent when CCTA was introduced to clinical practice in some pragmatic clinical trials [2, 3] .
Recently, CT-FFR, a kind of novel functional assessment derived from CCTA, dramatically increase specificity of diagnosis on flow limiting coronary stenosis, enabling CCTA to become a more robust non-invasive strategy. It showed a great potential in detecting functional myocardial ischemia related to coronary specific lesion (in Discovery-Flow, DEFACTO and NXT trial) [4] [5] [6] . Moreover, clinical care guided by CT-FFR could provide benefits with equivalent clinical outcomes and lower expenditure, compared with routine clinical care over 1-year follow-up (Platform trial) [7] . In addition, ADVANCE study revealed that CT-FFR modified treatment recommendation which might reduce unnecessary ICA, predict revascularization and further identify subjects at low risk of adverse events through 90 days [8] .
However, these studies was not randomized designed and selection bias still existed. Also, the cost-effective of CT-FFR in clinical practice remains to be determined, especially in developing countries. The purpose of this present study will be to evaluate whether CTA/CT-FFR outperforms the usual care in ruling out patients without significantly obstructive CAD before invasive catheterization and improving clinical prognosis during follow-up in a randomized design. 
Method

Setting
This multicentre randomized controlled clinical trial will be carried out in 6 tertiary hospitals across China, all of which has the volume of over 200 patients in out-patient area of cardiology division each working day. Participating subjects will be enrolled and subsequently assigned to either usual care group or CT-FFR care group via computergenerated random numbers (1:1 ratio) ( Figure. 1). The trial accords with SPIRIT guidelines.
Core lab has been established to receive all the imaging data for analysis, and two trained clinicians will conduct all of the measurements. The treatments (both intervention and control) will be delivered by licensed clinicians in the participating sites. The cardiologist will be aware of patients' group allocation because they will provide the trial intervention, but they will not be involved in the analysis. Data collectors and outcome adjudicators are blinded to treatment allocation.
Eligibility criteria 5
Inclusion criteria:
Consecutive patients with new onset chest pain suspicious for CAD will be included.
Subjects with intermediate-to-high likelihood of CAD will be recruited based on various typicality of chest pain. Another major inclusion criterion is the coronary CTA result which showed that the diameter stenosis is between 30% and 90% in at least one major coronary artery (coronary artery diameter ≥ 3 mm).
The typicality of the chest pain were determined by three characteristics of chest pain, including central chest discomfort lasting below 15 minutes, provoked by exertion or emotional stress, and relieved by rest or nitrates. This definition is similar with The NICE guideline update (2016) [9] . Non-anginal pain was defined as the presence or absence of only one characteristic of chest pain. Atypical angina was defined as the presence of two characteristic. Typical angina was defined as the presence of all three characteristic above. For the mild coronary stenosis(30-49%), patients with typical angina will be recruited. For the intermediate stenosis(50-69%), patients with atypical angina or nonanginal pain will be recruited. For the severe stenosis(70-90%), only patients with nonanginal pain will be included.
Agreement to participate in this trial will be necessary and informed consents will be obtained from all subjects before recruiting. 
Measurement
Coronary CTA image is obtained before the patient's first visit and assessement. When subjects are randomized to the CTA/CT-FFR arm, on-site FFR based on the coronary CTA imaging (DeepFFR V1.0.0, Beijing CuraCloud Technology Co., Ltd., Beijing, China) will be measured. DeepFFR workstation is very dedicated software utilizing the original CTA imaging to meter simulated FFR values in artificial intelligence (AI) model, which has been introduced in previous article [10] . The calculation process could be summarized as Lesion-specific CT-FFR is defined as simulated FFR value at distance of 20 mm away from lesion of interest.
Treatment arms
If the subjects are randomly allocated to CTA/CT-FFR arm, they will be examined by
DeepFFR for three major epicardial arteries. If the result of CT-FFR calculation is less than or equal to 0.8 in one or more major coronary arteries, the patient will be referred to ICA directly; if the result of CT-FFR value is more than 0.8, optimal medical therapy will be Multi-sites participating in this registry use standard multi-slice spiral CT scanner to scan and reconstruct coronary CTA images. The original imaging will be transfer to on-site workstation to complete DeepFFR measurement and the on-site lab will provide the report to the referral physician within 24 hours for decision making. 8 
Downstream decision making
The results of the index test will be provided to the reference cardiologist of the patients' institution who will make clinical decisions based on the integrated evaluation of patient clinical assessment and index test findings. The following downstream decision making will be recorded from study entry until the end of follow-up: [1] non-invasive diagnostic tests, including further stress testing (exercise or pharmacological stress), with detection of ischemia by ECG, myocardial perfusion, or wall motion abnormalities; [2] number of ICA and prevalence of non-obstructive CAD at ICA; [3] Goals of risk factors control by optimal medical therapy.
At baseline, 6 months and 12 months recommendations for therapy are made in line with guidelines published. The goal of anti-hypertensive therapy is to achieve a blood pressure of less than 140/90 mmHg. The choice of anti-hypertensive therapy will be left to the treating physician. The aim of anti-lipid therapy is to achieve levels of LDL < 1.9 mmol/l. In the first instance, statin therapy will be initiated and then increased with the addition of a second agent if necessary. In the case of diabetics with a raised blood sugar, the primary health care physician is asked to measure HbA1c and to ensure that the patients' subsequent therapy is tailored to achieve a HbA1c of less than 6.5 mg/dl. Smokers are referred to the smoking cessation clinic.
Follow-up
Subjects will be contacted regularly by trained interviewers at 90 days, 6 months and 12 months post-enrollment for follow-up assessment until death, withdrawal or end of the trial. All subjects are followed for a minimum of 12 months. An independent clinical events adjudication committee (CEC) reviewed all primary endpoint event and secondary endpoints in a blinded fashion. The decisions of CEC will be used to implement the final 9 statistical analysis.
A Clinical Research Organization (CRO) has been contracted to oversee the monitoring of all sites, establishing the eCRF and checking the completeness and consistency of the trial data.
E n d p o i n t o f t h e s t u d y
The primary endpoint of the present trial is comparison between the two arms in the rate of planned ICA without significant obstructive CAD within 90 days. Significant obstructive CAD is defined as more than or equal to 70% of area stenosis by quantitative analysis in core lab or invasive FFR ≤ 0.8 if available during procedure.
The secondary endpoint will be the comparison between the two treatment arms in terms of MACE, quality of life, cumulative effect dose of radiation exposure and overall medical cost during the follow-up at 1 year. 
Statistical analysis
Intention-to-treat analysis will be applied. All data statistical analysis will be performed pathway and accordingly endpoints. The hazards ratio (HR) is presented as 95% confidence intervals. P < 0.05 is considered as significance in statistics.
Data management and monitoring
All original data will be recorded in case report forms. The principal investigator of the present study (Yundai Chen) will supervise the conduct of the trial conduction and perform monthly audits of the trial.
Ethics statement
The study protocol is complied with the World Medical Association Declaration of Helsinki.
Ethical clearance for the TARGET trial has been obtained from the ethical committee of Chinese PLA general hospital. 11 
Discussion
The core goal of TARGET trial is to assess the effect of CT-FFR on clinical decision making to the patients with stable chest pain in comparison of standard of care group. The hypothesis is that CT-FFR guided clinical management may provide extra benefit in reducing the rate of planned ICA without obstructive CAD, decreasing patients' medical expenditure, and improving outcomes. This randomized control trial will help physicians to understand deeply the availability of CT-FFR as a non-invasive diagnostic method in the evaluation of myocardial ischemia.
Previous large cohort studies have confirmed the inconsistency between anatomical stenosis found by ICA and functional myocardial ischemia [11] [12] [13] . Due to the limitation of diagnosis based on coronary CTA imaging, it remains challenging to rely on anatomical evaluation solely for clinical management of patients. Although FFR measurement can be used to evaluate patients with stable chest pain during ICA, the risk of invasive procedure still exists. Moreover, some studies have demonstrated that less than half of patients with obstructive CAD were found by invasive angiography [14] . A study simultaneously evaluating anatomical and functional abnormality (COURAGE study) have found that only 32% of patients with severe coronary stenosis showed severe myocardial ischemia, while 40% showed no signs of ischemia or only mild ischemia [15] . These findings reflected the discrepancy between anatomical stenosis and myocardial ischemia, and functional assessment will be imperative for clinical management for the patients with stable chest pain.
Recently, CT-FFR technology brings out a new hope for anatomical and functional assessment in accuracy, simultaneously. RIPCORD study have shown that coronary CTA combined with CT-FFR may lead to more cautious for both ICA and followed PCI when treating patients with stable angina pectoris [16] . Therefore, this combined strategy implies important clinical reference in selection of examination, clinical decision making, improvement of prognosis, and reduction of expenditure. TARGET trial can better optimize the clinical management and improve the prognosis in a careful, strict, randomized controlled design. The prospective data derived from TARGET trial may assist us to answer this important question and provide more useful information.
Diagnostic performance of DeepFFR technique has been confirmed as previously described [10] . The calculating time has been dramatically reduced, so the waiting time for patients is greatly shortened. However, Previous CT-FFR strategy relies on the transfer of imaging data into the cloud or the core lad, which may increase time consumption and even induce the "black-box" effect. For on-site measurement, CT-FFR value can be feedback to physician within one day, which is conducive to rapid decision making downstream. On the other hand, clinical management based on DeepFFR may greatly reduce expenditure, save the cost of diagnosis and treatment, and will be more easily taken into practice in developing countries.
In conclusion, the purpose of the TARGET trial is to evaluate whether clinical decisions based on CT-FFR measurements could decrease unnecessary ICA, optimize diagnostic and therapeutic procedures, reduce radiation exposure, save medical expenditure and improve prognosis in comparison of conventional management for patients with stable chest pain.
The effect will be assessed by the rate of non-obstructive CAD in planned ICA within 90 13 days and MACE within 12 months. Additionally, the impact includes QOL, reduction of cumulative radiation exposures and medical expenditure within 12 months because of reduction of overuse of invasive procedure will be evaluated as well. In brief, the TARGET trial aims to provide a new concept on health care for the management of suspect CAD patients in China.
Trial Status
The current protocol is version 2.0 (201812) and was issued on 1 January 2018. The flow chart of TARGET trial. To evaluate the effect of CT-FFR care strategy on improving decision making management, subjects enrolled will be randomized into either standard of care arm or CT-FFR care arm. 
Recruitment of patients and data collection started in
